Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Evidence for the Formation of Benzacridine Derivatives in Alkaline-Treated Sunflower Meal and Model Solutions.

Bongartz V, Brandt L, Gehrmann ML, Zimmermann BF, Schulze-Kaysers N, Schieber A.

Molecules. 2016 Jan 14;21(1):91. doi: 10.3390/molecules21010091.

2.

Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients.

Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE, Multhoff G.

Radiother Oncol. 2016 Jan;118(1):176-80. doi: 10.1016/j.radonc.2015.11.016.

PMID:
26683801
3.

Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles.

Gehrmann MK, Kimm MA, Stangl S, Schmid TE, Noël PB, Rummeny EJ, Multhoff G.

Int J Nanomedicine. 2015 Sep 8;10:5687-700. doi: 10.2147/IJN.S87174.

4.

Role of membrane Hsp70 in radiation sensitivity of tumor cells.

Murakami N, Kühnel A, Schmid TE, Ilicic K, Stangl S, Braun IS, Gehrmann M, Molls M, Itami J, Multhoff G.

Radiat Oncol. 2015 Jul 22;10:149. doi: 10.1186/s13014-015-0461-1.

5.

Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer.

Honig A, Gehrmann M, Kranke P, Keller D, Engel JB, Hengstler S, Schmidt M.

Eur J Gynaecol Oncol. 2014;35(5):503-7.

PMID:
25507416
6.

Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer.

Honig A, Gehrmann M, Kranke P, Keller D, Engel JB, Hengstler S, Schmidt M.

Eur J Gynaecol Oncol. 2014;35(5):503-7.

PMID:
25423693
7.

Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide.

Gehrmann M, Stangl S, Foulds GA, Oellinger R, Breuninger S, Rad R, Pockley AG, Multhoff G.

PLoS One. 2014 Aug 28;9(8):e105344. doi: 10.1371/journal.pone.0105344.

8.

Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, Specht HM, Multhoff G.

Front Immunol. 2014 Jul 1;5:307. doi: 10.3389/fimmu.2014.00307.

9.

Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck.

Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, Breuninger S, Hube K, Lehnerer S, van Phi V, Sage E, Schmid TE, Sedelmayr M, Schilling D, Sievert W, Stangl S, Multhoff G.

Radiat Oncol. 2014 Jun 9;9:131. doi: 10.1186/1748-717X-9-131.

10.

Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models.

Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):694-700. doi: 10.1016/j.ijrobp.2013.11.008.

PMID:
24521683
11.

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG)..

Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671.

12.

Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells.

Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C, Gehrmann M, Rödel C, Kreuter J, Rödel F.

J Control Release. 2013 Nov 28;172(1):201-6. doi: 10.1016/j.jconrel.2013.08.020.

PMID:
24008150
13.

Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.

Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR.

Mol Cancer Res. 2013 Aug;11(8):901-11. doi: 10.1158/1541-7786.MCR-12-0699.

14.

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.

Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A, Solbach C, Hellwig B, Rahnenführer J, Koelbl H, Gehrmann M, Marchan R, Cadenas C, Hengstler JG, Schmidt M.

BMC Cancer. 2012 Nov 27;12:562. doi: 10.1186/1471-2407-12-562.

15.

Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors.

Schmidt M, Micke P, Gehrmann M, Hengstler JG.

Oncoimmunology. 2012 Oct 1;1(7):1156-1158.

16.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475.

17.

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG)..

Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334.

18.

Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.

Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A, Battista M, Sicking I, Cotarelo C, Cadenas C, Marchan R, Stewart JD, Gehrmann M, Koelbl H, Hengstler JG, Schmidt M.

PLoS One. 2012;7(9):e44741. doi: 10.1371/journal.pone.0044741.

19.

Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response.

Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, Lohr M, Gehrmann M, Rahnenführer J, Schmidt M, Hengstler JG.

Breast Cancer. 2014 Jul;21(4):491-9. doi: 10.1007/s12282-012-0404-8.

PMID:
23001506
20.

Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B.

Gehrmann M, Stangl S, Kirschner A, Foulds GA, Sievert W, Doss BT, Walch A, Pockley AG, Multhoff G.

PLoS One. 2012;7(7):e41341. doi: 10.1371/journal.pone.0041341.

Items per page

Supplemental Content

Loading ...
Support Center